Investigational Drug Information for Barusiban
✉ Email this page to a colleague
What is the drug development status for Barusiban?
Barusiban is an investigational drug.
There have been 4 clinical trials for Barusiban.
The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2016.
The most common disease conditions in clinical trials are Premature Birth, Obstetric Labor, Premature, and Infertility. The leading clinical trial sponsors are Ferring Pharmaceuticals, Tel-Aviv Sourasky Medical Center, and [disabled in preview].
There are ten US patents protecting this investigational drug and one hundred and sixty-three international patents.
Summary for Barusiban
| US Patents | 10 |
| International Patents | 163 |
| US Patent Applications | 36 |
| WIPO Patent Applications | 35 |
| Japanese Patent Applications | 6 |
| Clinical Trial Progress | Phase 2 (2016-03-01) |
| Vendors | 12 |
Recent Clinical Trials for Barusiban
| Title | Sponsor | Phase |
|---|---|---|
| Tocolytic Therapy for Preterm Labor in Multiple Gestation | Tel-Aviv Sourasky Medical Center | Phase 3 |
| Barusiban Subcutaneously for Reducing Implantation Failure Due to Uterine Contractions | Ferring Pharmaceuticals | Phase 2 |
| Effect of Oxytocin Antagonist on Reduction of Uterine Contractions | Ferring Pharmaceuticals | Phase 2 |
Clinical Trial Summary for Barusiban
Top disease conditions for Barusiban
Top clinical trial sponsors for Barusiban
US Patents for Barusiban
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Barusiban | ⤷ Sign Up | Permeant delivery system and methods for use thereof | NITTO DENKO CORPORATION (Tokyo, JP) | ⤷ Sign Up |
| Barusiban | ⤷ Sign Up | Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof | Merck Serono S.A. (Coinsins, CH) | ⤷ Sign Up |
| Barusiban | ⤷ Sign Up | 1H-pyrazoles useful in therapy | Pfizer Inc (New York, NY) | ⤷ Sign Up |
| Barusiban | ⤷ Sign Up | Pyrrolidines | Pfizer Inc. (New York, NY) | ⤷ Sign Up |
| Barusiban | ⤷ Sign Up | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs | Ascendis Pharma AS (Hellerup, DK) | ⤷ Sign Up |
| Barusiban | ⤷ Sign Up | Prodrugs and drug-macromolecule conjugates having controlled drug release rates | ProLynx LLC (San Francisco, CA) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Barusiban
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Barusiban | Australia | AU2009231739 | 2028-03-31 | ⤷ Sign Up |
| Barusiban | Canada | CA2720067 | 2028-03-31 | ⤷ Sign Up |
| Barusiban | Canada | CA3084317 | 2028-03-31 | ⤷ Sign Up |
| Barusiban | Canada | CA3138128 | 2028-03-31 | ⤷ Sign Up |
| Barusiban | China | CN102088935 | 2028-03-31 | ⤷ Sign Up |
| Barusiban | China | CN105126241 | 2028-03-31 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
